ArticleBMC infectious diseases2026
Influencing factors and clinical characteristics of severe fever with thrombocytopenia syndrome complicated with invasive pulmonary aspergillosis.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo investigate the clinical characteristics and risk factors of invasive pulmonary aspergillosis (IPA) in patients with severe fever with thrombocytopenia syndrome (SFTS).
methodsWe conducted a retrospective analysis of 136 SFTS patients hospitalized at Zhongnan Hospital of Wuhan University between January 2017 and May 2024. Patients were stratified into IPA (n = 33) and non-IPA (n = 103) groups. Demographics, comorbidities, laboratory parameters, interventions, and outcomes were compared. Univariate and multivariate analyses were employed to evaluate the influencing factors, and Kaplan-Meier curves were utilized to assess survival outcomes.
resultsCompared to the non-IPA group, the IPA group was associated with significantly higher rates of severe disease (93.94% vs. 43.69%, P < 0.001), mortality (42.42% vs. 6.80%, P < 0.001) and ICU admission (63.64% vs. 17.48%, P < 0.001). Survival analysis revealed a significantly lower survival rate than that of the non-IPA group. Patients with IPA were older (69 vs. 65 years, P = 0.026) and more likely to have pre-existing diabetes (27.27% vs. 8.74%, P = 0.006) or hypertension (45.45% vs. 23.30%, P = 0.014). Laboratory analyses demonstrated significantly elevated markers of multi-organ damage in IPA group, including hepatic (ALT, AST, albumin), cardiac (Troponin I, CK, CK-MB), Pancreas (amylase, lipase) and renal (Creatinine) dysfunction indicators (P < 0.05), along with heightened inflammatory responses evidenced by increased IL-6 (P < 0.001), PCT (P < 0.001) and CRP (P = 0.038) levels. Immunological assessment revealed profound lymphocyte depletion in IPA group, particularly affecting CD4⁺ T cells (124 vs. 324 cells/µL), CD8⁺ T cells (86.5 vs. 327 cells/µL), and NK cells (40.5 vs. 139.5 cells/µL) (all P < 0.001). Notably, IPA patients exhibited substantially higher viral loads (208,000 vs. 3,535 copies/mL, P < 0.001). Multivariate analysis identified diabetes (OR [5.809], P = 0.013) and severe disease at admission (OR [7.111], P = 0.022) as independent risk factors for IPA development.
conclusionIPA profoundly impairs clinical outcomes in SFTS patients, emphasizing the importance of early identification and immediate therapeutic intervention. Particular vigilance should be maintained for high-risk populations, including diabetic patients and those with severe SFTS manifestations, through intensified surveillance and rapid antifungal therapy to mitigate mortality and improve prognostic trajectories. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.